


High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure



CONCLUSION

In patients with COVID-19 infection and acute hypoxemic respiratory failure, high dose dexamethasone therapy did not significantly alter 60-day mortality and different respiratory support strategy did not affect 28-day requirement for invasive mechanical ventilation.